Fourteen early-stage companies committed to improving patient outcomes will receive mentorship, introductions, and fundraising support to advance their solutions.
One Mind, a leading nonprofit focused on mental health based in Napa Valley, California, has revealed the startups selected for the 2026 One Mind Accelerator. This intensive 10-week program is designed to provide hands-on support and expert guidance in business development, company growth, fundraising, and founder mentorship.
The 2026 cohort marks the fourth since the Accelerator’s launch in 2023. Fourteen companies were chosen from a record number of applicants, representing less than five percent of submissions. With this selection, the One Mind Accelerator portfolio now includes 51 companies. The first 37 startups have collectively raised nearly one billion dollars since their Demo Days and have impacted more than one million people with lived mental health experience.
Health Technology Insights: ConcertAI Uses Agentic AI to Accelerate Clinical Trials
This year’s cohort spans pre-seed, seed, and Series A stages and focuses on innovations across the full spectrum of mental health care, from early-stage behavioral challenges to serious psychiatric disorders, and from pediatric to geriatric care. These companies are leveraging advances in clinical AI, spatial computing, biomarkers, and non-invasive brain imaging and stimulation, along with growing emphasis on policy and lifestyle-based interventions for chronic mental health conditions.
The 14 startups selected for 2026 include Biomia, a biotech company developing nature-inspired small molecule therapeutics for CNS disorders such as schizophrenia; Birches Health, a digital behavioral health provider focusing on addiction and impulse-control disorders; Eratos Therapeutics, which uses AI-driven brain maps to identify therapeutic targets for precision CNS drug development; Flow Neuroscience, offering FDA-approved at-home electric medicine for mental health; Forecast Bio, an AI platform linking cellular neurobiology to mental health outcomes to accelerate drug development; Limbic, an AI mental health agent serving health systems and payers in the UK and US; Manatee, which treats pediatric mental health within the family context; Monument Therapeutics, using digital biomarkers for targeted neurological and psychiatric therapies; Neurofundus, developing precision psychiatry through disease subtype mapping; Nosis Health, integrating addiction medicine with diagnostics, therapy, and lifestyle support; Orbit Neuro, building neural foundation models for precision mental healthcare; Radicle Science, combining AI, consumer science, and clinical trials to create accessible nonprescription mental health solutions; SocialRx, a social prescribing platform addressing loneliness and mental health; and Vitalic Health, specializing in proactive geriatric behavioral healthcare.
Health Technology Insights: NuvemRx Acquires par8o to Expand Specialty Care Capabilities
“This year’s cohort represents the forefront of mental health science and innovation. As technology and AI redefine what is possible, these founders are ready to deliver meaningful improvements in mental healthcare for individuals and families,” said Kathleen M. Pike, PhD, CEO of One Mind.
The 2026 program begins with a week of in-person sessions in Menlo Park, California, from February 9 to 13, followed by eight weeks of virtual training, and concludes with an in-person Demo Day on April 15. One Mind provides each cohort with access to its network of entrepreneurs, investors, mental health advocates, operators, payers, providers, and scientists, who serve as mentors and subject matter experts.
“Since its inception, the Accelerator has helped early-stage companies bring mental health innovations to market faster and with greater impact,” said Carmine Di Maro, Executive Director of the One Mind Accelerator. “The program tailors support to the specific growth stage of each company, fostering relationship-building, business development, and fundraising. Over the past three years, the Accelerator has facilitated more than one thousand introductions and hosted over 300 expert sessions, leading to closed contracts, advisory board recruitment, and executive hiring.”
Highlights from the opening week include a keynote by Russell Glass, former CEO of Headspace, as well as panels with senior representatives from state and local governments, federal agencies, investors, payers, and healthcare providers. Panelists come from organizations such as the California Commission for Behavioral Health, Los Angeles County Department of Mental Health, Advanced Research Projects Agency for Health, National Institute of Mental Health, Cigna Healthcare, CVS Health, Intermountain Healthcare, Kaiser Permanente, and UC Davis.
As a 501(c)(3) nonprofit, One Mind is supported by private donors, foundations, and corporate sponsors, including Bank of America, Baszucki Group, Penner Family Foundation, and Resonance Philanthropies. Additional support comes from the Anthony Pritzker Family Foundation, The Dr. Daniel C. Cooper Brain Health Research Fund, Flourish Impact Fund, Greenbridge Family Foundation, Rainwater Foundation, Unlikely Collaborators, the Wellcome Trust, and generous contributions from an anonymous donor and the One Mind Board of Directors.
“One Mind Accelerator has been instrumental in fostering innovative teams capable of transforming patient care, particularly in youth mental health, an area we have supported for over three decades,” said Sheri Sobrato, Founder of Resonance Philanthropies, a longtime supporter of the Accelerator.
Health Technology Insights: Ambry Genetics Hits One Million RNA-Based Diagnostic Tests
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
